89466-60-4

Upstream product

• 5346-53-2 5-amino-4-cyano-1-(2-hydroxyethyl)-pyrazole 

Downstream Products

• 1361961-43-4 1-(2-chloroethyl)-6-(difluro-(4-fluorophenyl)methyl)-N-(5-methyl-1H-pyrazol-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 
• 1361960-73-7 6-(difluro-(4-fluorophenyl)methyl)-N-(5-methyl-1H-pyrazol-3-yl)-1-vinyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine 
• 1361961-41-2 1-(2-chloroethyl)-6-(difluro-(4-fluorophenyl)-methyl)-1H-pyrazolo[3,4-d]pyrimidin-4-ol 
• 1361960-72-6 6-(difluro-(4-fluorophenyl)methyl)-N-(5-methyl-1H-pyrazol-3-yl)-1-(2-morpholinoethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 
• 99228-09-8 5-(1-Oxo-6-(2-propenyl)-2-cyclohexen-3-yl)amino-1-(2-chloroethyl)-4-cyanopyrazole 

Relevant academic research and scientific papers

AZOLOPYRIDINE AND AZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF

Provided herein are azolopyridine and azolopyrimidine compounds for treatment of JAK kinase mediated diseases, including JAK2 kinase-, JAK3 kinase- or TYK2 kinase-mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.

Pyrazolo[3,4-b]pyrrolo[3,4-e]pyridine-5(1H)-one and 1-H-pyrazolo[3,4-b][1,6]naphthyridine-5(6H)-one derivations, useful as anti-anxiety agents

Novel pyrazolo[3,4-b]pyridine lactams which are useful as anxiolytics are disclosed including methods of preparation, pharmaceutical compositions containing them and intermediates used in their preparation.

Pyrazolopyridine cycloalkanones and process for their preparation

Novel tetrahydropyrazolo-[3,4-b]quinolinones, cyclopenta[b]pyrazolo-[4,3-e]pyridinones and cyclohepta[b]-pyrazolo[4,3-e]pyridinones, useful as anxiolytics having reduced side effects, are disclosed, including methods of preparation, pharmaceutical compositions containing them and intermediates used in their preparation.